Proteomic profiling reveals antitumor effects of RT2 peptide on a human colon carcinoma xenograft mouse model
2
Issued Date
2022-02-15
Resource Type
ISSN
00142999
eISSN
18790712
Scopus ID
2-s2.0-85123117243
Pubmed ID
35032485
Journal Title
European Journal of Pharmacology
Volume
917
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Pharmacology Vol.917 (2022)
Suggested Citation
Maijaroen S., Klaynongsruang S., Reabroi S., Chairoungdua A., Roytrakul S., Daduang J., Taemaitree L., Jangpromma N. Proteomic profiling reveals antitumor effects of RT2 peptide on a human colon carcinoma xenograft mouse model. European Journal of Pharmacology Vol.917 (2022). doi:10.1016/j.ejphar.2022.174753 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86879
Title
Proteomic profiling reveals antitumor effects of RT2 peptide on a human colon carcinoma xenograft mouse model
Other Contributor(s)
Abstract
A comparative study of human colon HCT-116 xenograft in nude mice treated with and without peptide RT2 at high doses is performed along with a label-free proteomic analysis of the tissue in order to understand the potential mechanisms by which RT2 acts in vivo against colorectal tumors. RT2 displays no significant systematic toxicity, but reduces tumor growth after either intraperitoneal or intratumoral injection demonstrating it is a safe and efficacious antitumor agent in vivo. Of the 3196 proteins identified by label-free proteomics, 61 proteins appear only in response to RT2 and are involved in cellular processes largely localized in the cells and cell parts. Some of the proteins identified, including CFTR, Wnt7a, TIA1, PADI2, NRBP2, GADL1, LZIC, TLR6, and GPR37, have been reported to suppress tumor growth and are associated with cell proliferation, invasion, metastasis, angiogenesis, apoptosis, and immune evasion. Our work supports their role as tumor biomarkers and reveals RT2 has a complex mechanism of action in vivo.